News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
46 Results
Type
Article (3)
Company Profile (1)
Press Release (42)
Section
Business (25)
Drug Development (4)
FDA (2)
News (25)
Tag
Alliances (3)
Approvals (2)
Clinical research (1)
Cystic fibrosis (1)
Diagnostics (1)
Earnings (1)
Events (4)
FDA (2)
Healthcare (1)
Medical device (1)
Medtech (1)
NextGen Class of 2024 (6)
People (12)
Postmarket research (1)
Preclinical (2)
Rare diseases (1)
Startups (4)
United States (2)
Date
Last 365 days (3)
2024 (2)
2023 (5)
2022 (3)
2021 (3)
2020 (4)
2019 (4)
2018 (3)
2017 (6)
2016 (6)
2015 (3)
2014 (3)
2013 (3)
2012 (1)
46 Results for "alcresta".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Alcresta Therapeutics Announces Commercial Availability of Next-Generation RELiZORB® (iMMOBILIZED LIPASE) Cartridge
Alcresta Therapeutics, Inc. today announced the commercial availability of the next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge.
May 13, 2024
·
3 min read
Genetown
Alcresta Therapeutics Announces FDA Clearance for the Next-Generation RELiZORB® Digestive Enzyme Cartridge
Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced 510(k) clearance of its next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
December 21, 2023
·
4 min read
Genetown
Alcresta Therapeutics Announces Publication of Cystic Fibrosis Foundation Position Paper Confirming Inline Enzyme Cartridges are Safe and Effective
Alcresta Therapeutics, Inc. today announced the publication of a position paper in the May issue of the Journal of Cystic Fibrosis.
July 25, 2023
·
2 min read
Genetown
Alcresta Therapeutics Announces FDA Expanded Use Clearance for RELiZORB® (iMMOBILIZED LIPASE) Cartridge for Pediatric Patients Ages 2 to 5 Years
Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that the U.S. Food and Drug Administration (FDA) has cleared expanded use of RELiZORB® to children ages 2 to <5 years.
August 31, 2023
·
3 min read
Drug Development
Alcresta Therapeutics Announces Preclinical Data Showing ALC-078 Cartridge Use in SBS Model Associated with Reduced Dependence on Parenteral Nutrition
Alcresta Therapeutics, Inc. today announced publication of preclinical data from the company’s development device ALC-078 in a porcine short bowel syndrome (SBS) model.
March 16, 2023
·
5 min read
Business
Alcresta Therapeutics Announces Series of Commercial Milestone Achievements for RELiZORB®
Alcresta Therapeutics, Inc. today announced a series of commercial milestone achievements.
April 1, 2022
·
2 min read
Business
Alcresta Therapeutics Announces Appointment of Chris Parrish as Chief Operations Officer
Alcresta Therapeutics, Inc. announced the appointment of Chris Parrish as its Chief Operations Officer (COO) effective November 29, 2021.
November 29, 2021
·
2 min read
Drug Development
Alcresta Therapeutics Announces Preclinical Data Showing ALC-078 Cartridge Use in SBS Model Was Associated with Improved Fat and Nutrient Absorption
Alcresta Therapeutics, Inc. today announced publication of preclinical data from the company’s development device, ALC-078, in a porcine short bowel syndrome (SBS) model.
April 27, 2022
·
4 min read
Genetown
Alcresta Therapeutics Announces Medicare Local Coverage Determination that Confirms Coverage for RELiZORB®
Alcresta Therapeutics, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has published a Local Coverage Determination (LCD) on enteral nutrition (LCD ID No. 38955) that confirms coverage for RELiZORB® (immobilized lipase).
September 7, 2021
·
2 min read
Business
Alcresta Therapeutics Appoints Alan Muney, MD To Board Of Directors
Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the appointment of Alan Muney, MD to its Board of Directors.
December 7, 2020
·
3 min read
1 of 5
Next